Aurobindo Pharma’s Subsidiary CuraTeQ Secures UK Approval for Bevacizumab Biosimilar

SCG Cell Therapy Partners with A*STAR BTI and NATi to Advance RNA-Based Therapeutics

Korea's National Bio Big Data Project: Advancing Precision Medicine with Macrogen and Illumina

GST Exemption Announced for Cancer Treatment Gene Therapy

AIIMS Develops Affordable CAR-T Cell Therapy for Multiple Myeloma

Sangamo Therapeutics and Astellas Collaborate on Innovative Gene Therapy for Neurological Diseases

FDA Clears IND for Arbor Biotechnologies’ ABO-101 Gene Editing Therapeutic for Primary Hyperoxaluria Type 1

Fortis Healthcare Acquires Stake in Agilus Diagnostics

FDA Approves BRAFTOVI® Combination Regimen as First-Line Treatment for BRAF V600E-Mutant Metastatic Colorectal Cancer

The Role of Big Data in Precision Medicine

Caris Life Sciences Celebrates 1,000+ Precision Medicine Studies, Advancing Cancer Research and Patient Outcomes

OncoHelix and Qualisure Diagnostics Partner to Bring Thyroid GuidePx® Test to Canadian Patients

Gates Foundation Invests $50 Million in Tessera Therapeutics to Advance Gene Therapy for Sickle Cell Disease

FDA Approves Ensartinib (Ensacove) as First-Line Treatment for ALK-Positive NSCLC

Guardant Health and Boehringer Ingelheim Collaborate to Advance Liquid Biopsy CDx for HER2-Targeted Therapy in NSCLC

Home
/
insight
/
details

Elevating Bladder Cancer Diagnosis: Liquid Biopsy and Protein Markers in Focus

NextEdge Admin

07 May 2024

2 min 43 sec

Diagnostic,non-invasive,Screening,Liquid Biopsy

Bladder cancer diagnosis has undergone significant advancements, with liquid biopsy emerging as a promising non-invasive approach. This method utilizes urine samples to detect various biomarkers, providing valuable insights into cancer presence, progression, and treatment responses.

Liquid biopsy in bladder cancer detection analyzes circulating tumor cells, cell-free DNA, RNA, and proteins in urine, offering a non-invasive and sensitive method for early cancer detection, prognosis assessment, and treatment monitoring.

Molecular tests play a pivotal role in liquid biopsy for bladder cancer detection. The Multigene RNA Test, Cxbladder®, evaluates the expression profiles of five gene biomarkers from urine samples. By analyzing CDC2, HOXA13, MDK, IGFBP5, and CXCR5, Cxbladder calculates a risk score, aiding in early detection and prognosis assessment. Additionally, the Epigenetic Profile Test, AssureMDx TM, examines the methylation status of genes like TWIST1, ONECUT2, and OTX1, along with mutation analyses of FGFR3, TERT, and HRAS, providing comprehensive insights into bladder cancer presence and prognosis.

Protein markers further enhance liquid biopsy for bladder cancer diagnosis. Nuclear Matrix Protein 22 (NMP22) detection in urine indicates cell disintegration, serving as a marker for bladder cancer. Available as a rapid point-of-care or laboratory-based assay, NMP22 offers sensitive detection. Bladder Tumour Antigen (BTA) identifies human complement factor H related protein in urine, produced by bladder cancer cells, aiding in early detection through rapid point-of-care testing. The Cytokeratin Fragment Test (UBC) measures cytokeratin 8 and 18 fragments in urine, providing convenient and accurate diagnosis.

Liquid biopsy, coupled with molecular tests and protein markers, revolutionizes bladder cancer diagnosis. These advancements promise greater accuracy, convenience, and patient-centered care, leading to improved clinical outcomes and enhanced quality of life for bladder cancer patients.